Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial is studying how well sulindac works in preventing melanoma in
healthy participants who are at increased risk of melanoma. Sulindac may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known
whether sulindac is more effective than a placebo in preventing melanoma in individuals with
many moles and abnormal moles.